David Kylhammar
Overview
Explore the profile of David Kylhammar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Toren K, Schioler L, Lindberg A, Andersson A, Behndig A, Bergstrom G, et al.
BMJ Open Respir Res
. 2020 Aug;
7(1).
PMID: 32759170
Background: The diagnosis of chronic obstructive pulmonary disease is based on the presence of persistent respiratory symptoms and chronic airflow limitation (CAL). CAL is based on the ratio of forced...
12.
Sandqvist A, Kylhammar D, Bartfay S, Hesselstrand R, Hjalmarsson C, Kavianipour M, et al.
Scand Cardiovasc J
. 2020 Jun;
55(1):43-49.
PMID: 32586166
To investigate if the pulmonary arterial hypertension (PAH) risk assessment tool presented in the 2015 ESC/ERS guidelines is valid for patients with chronic thromboembolic pulmonary hypertension (CTEPH) when taking pulmonary...
13.
Kjellstrom B, Nisell M, Kylhammar D, Bartfay S, Ivarsson B, Radegran G, et al.
ERJ Open Res
. 2019 Aug;
5(3).
PMID: 31423450
Background: Women with idiopathic pulmonary arterial hypertension (IPAH) have been found to have a worse haemodynamic status at diagnosis, but better survival than men. Over the past decade, demographics have...
14.
Kjellstrom B, Hjalmarsson C, Kylhammar D, Radegran G
Expert Rev Cardiovasc Ther
. 2018 Nov;
17(1):1-2.
PMID: 30422719
No abstract available.
15.
Hjalmarsson C, Radegran G, Kylhammar D, Rundqvist B, Multing J, Nisell M, et al.
Eur Respir J
. 2018 Apr;
51(5).
PMID: 29622568
Recent reports from worldwide pulmonary hypertension registries show a new demographic picture for patients with idiopathic pulmonary arterial hypertension (IPAH), with an increasing prevalence among the elderly.We aimed to investigate...
16.
Sandqvist A, Schneede J, Kylhammar D, Henrohn D, Lundgren J, Hedeland M, et al.
Heart Vessels
. 2017 Oct;
33(3):255-263.
PMID: 28975394
Pulmonary arterial hypertension (PAH) is a life-threatening condition, characterized by an imbalance of vasoactive substances and remodeling of pulmonary vasculature. Nitric oxide, formed from L-arginine, is essential for homeostasis and...
17.
Kylhammar D, Radegran G
Lakartidningen
. 2017 Jul;
114.
PMID: 28742187
Pulmonary hypertension due to lung diseases In 2015 the European Society of Cardiology and European Respiratory Society published new guidelines on the diagnosis and treatment of pulmonary hypertension (PH). PH...
18.
Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, et al.
Eur Heart J
. 2017 Jun;
39(47):4175-4181.
PMID: 28575277
Aims: Guidelines recommend a goal-oriented treatment approach in pulmonary arterial hypertension (PAH). The aim is to reach a low-risk profile, as determined by a risk assessment instrument. This strategy is...
19.
Kylhammar D, Bune L, Radegran G
Eur J Appl Physiol
. 2014 Jun;
114(9):1995-2006.
PMID: 24929904
Purpose: To investigate the role of P2Y₁ and P2Y₁₂ receptors in hypoxia- and adenosine diphosphate (ADP)-induced pulmonary vasoconstriction. Methods: 19 anaesthetized, mechanically ventilated pigs (31.3 ± 0.7 kg) were evaluated...
20.
Kylhammar D, Persson L, Hesselstrand R, Radegran G
Scand Cardiovasc J
. 2014 Jun;
48(4):223-33.
PMID: 24912571
Objectives: To investigate survival, treatment escalation, effects of first-line single- and first-line combination therapy and prognostic markers in idiopathic- (IPAH), hereditary- (HPAH) and connective tissue disease-associated (CTD-PAH) pulmonary arterial hypertension...